These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25438678)

  • 1. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
    Dilla T; Möller J; O'Donohoe P; Álvarez M; Sacristán JA; Happich M; Tockhorn A
    BMC Psychiatry; 2014 Dec; 14():298. PubMed ID: 25438678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
    Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
    J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G; Heeg B; van Hout BA; Mehnert A
    Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
    Zeidler J; Mahlich J; Greiner W; Heres S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
    Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
    Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
    Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
    Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
    Chue PS; Heeg B; Buskens E; van Hout BA
    Pharmacoeconomics; 2005; 23 Suppl 1():62-74. PubMed ID: 16416762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.
    Wu DB; Lee EH; Chung WS; Chow DP; Lee VW; Wong MC; Lee KK
    Psychiatry Res; 2013 Dec; 210(3):745-50. PubMed ID: 24012164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care.
    Niaz OS; Haddad PM
    Acta Psychiatr Scand; 2007 Jul; 116(1):36-46. PubMed ID: 17559599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.
    Chue P; Chue J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):259-69. PubMed ID: 22812548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
    Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
    Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
    Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
    J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.